Articles Archive - Bioduro

Let's talk
Contact us

2017.03.29

BioDuro launches humanized tumor microenvironment, three-dimensional drug screening and patient-derived xenograft verification platform: hTME-3DX Screen and Verify™

A drug screening platform combining humanized 3D cell culture and patient-derived xenograft models, across a set of 300 proprietary tumor models.

November 2016
New Strategies Required to Meet Changing Needs in the Analytical Services Market
November 2016
BioDuro Increases Spray Dried Drug Product Manufacturing Capacity
September 2016
BioDuro Completes Infrastructure Expansion in Shanghai
June 2016
BioDuro Launches as Unique Contract Research and Drug Manufacturing Organization
April 2016
Integrating Drug Discovery and Development to Improve Efficiency and Candidate Success
January 2016
BioDuro, LLC Adds Industry Veteran CFO to Executive Team
December 2015
BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics
November 2015
BioDuro, LLC Announces Merger with Formex, LLC, and New Leadership
August 2015
Formex Acquires Gerteis MINI-PACTOR™ and Korsch XL 100™